Health
New Cancer Vaccine Trial Shows Why Recurrence-Free Survival Matters
A major melanoma study reported that approximately 82 percent of patients receiving a personalized mRNA vaccine plus standard immunotherapy were free from recurrence at the reported two-year point,…